{"id":"flupentixol-melitracen-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Anticholinergic effects (dry mouth, constipation, urinary retention)"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL110094","moleculeType":"Small molecule","molecularWeight":"291.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination where flupentixol acts as a dopamine antagonist to reduce psychotic symptoms, and melitracen enhances monoamine neurotransmission by blocking reuptake of norepinephrine and serotonin to treat depression and anxiety. The combination is designed to address both psychotic and affective symptoms in conditions such as depression with psychotic features or schizoaffective disorder.","oneSentence":"Flupentixol is a typical antipsychotic that blocks dopamine D2 receptors, while melitracen is a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake, together providing antipsychotic and antidepressant effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:35.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Depression with psychotic features"},{"name":"Schizoaffective disorder"}]},"trialDetails":[{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":"Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug","enrollment":88},{"nctId":"NCT03472651","phase":"PHASE1","title":"Bioequivalence Study to Compare Two Formulations of Deanxit®","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-05-07","conditions":"Healthy","enrollment":60},{"nctId":"NCT04970667","phase":"PHASE4","title":"Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":"Emotional Disorder, Neurologic Disorder","enrollment":100},{"nctId":"NCT03205228","phase":"PHASE3","title":"Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-07","conditions":"Globus","enrollment":40},{"nctId":"NCT01851863","phase":"PHASE4","title":"Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2013-05","conditions":"Dyspepsia, Compliance, Depression","enrollment":262},{"nctId":"NCT02179931","phase":"PHASE1","title":"Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-06","conditions":"Healthy Men and Women","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Flupentixol melitracen tablets","genericName":"Flupentixol melitracen tablets","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flupentixol is a typical antipsychotic that blocks dopamine D2 receptors, while melitracen is a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake, together providing antipsychotic and antidepressant effects. Used for Depression with psychotic features, Schizoaffective disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}